Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2008

01-07-2008 | Original Article

Syndrome of inappropriate secretion of antidiuretic hormone after chemotherapy with vinorelbine

Authors: Hiroaki Kuroda, Masafumi Kawamura, Tai Hato, Kazunori Kamiya, Masahiro Kawakubo, Yotaro Izumi, Masazumi Watanabe, Hirohisa Horinouchi, Koichi Kobayashi

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2008

Login to get access

Abstract

Purpose

To describe a case of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after administration of vinorelbine (VNB) for recurrence of lung cancer.

Case

A 76-year-old man underwent bronchial arterial infusion (BAI) of VNB for postoperative recurrence of lung cancer. Seven days later, hyponatremia and natriuresis developed. Based on his clinical and laboratory findings, we diagnosed him with SIADH. He improved within a couple of days with fluid restriction only.

Conclusions

Administration of VNB may potentially cause SIADH. This is the second report of the SIADH caused by VNB. It is important to monitor the serum sodium level and clinical findings after chemotherapy with VNB.
Literature
1.
Schwartz WB, Bennet W, Curelop S, et al (1957) A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23:529–542PubMedCrossRef
2.
Bartter FC, Schwartz WB (1967) The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42:790–806PubMedCrossRef
3.
Reynolds RM, Seckl JR (2005) Hyponatraemia for the clinical endocrinologist. Clin Endocrinol 63:366–374CrossRef
4.
Tho LM, Ferry DR (2005) Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to small cell variety? Postgrad Med J 81:e17PubMedCrossRef
5.
Sorensen JB, Anderson, Hansen HH (1995) Syndrome of inappropriate of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 238:97–110PubMedCrossRef
6.
Fraschini G, Recchia F, Holmes FA (1987) Syndrome of inappropriate antidiuretic hormone secretion associated with hepatic arterial infarction of vinblastine in three patients with breast cancer. Tumor 73:513–516
7.
Robertson GL, Bhoopalam N, et al (1973) Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 132:717–720PubMedCrossRef
8.
Kawamae K, Ganaha F, et al (1993) A case of inappropriate secretion of antidiuretic hormone (SIADH) and renal dysfunction by cisplatin. ICU CCU 17:587–592
9.
Garrett CA, Simpson TA Jr (1998) Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. Ann Pharmacother 32:1306–1309PubMedCrossRef
10.
Stuart MJ, Cuaso C, et al (1975) Sydrome of recurrent increased secretion of hormone following multiple doses of vincristine. Blood 45:315–320PubMed
Metadata
Title
Syndrome of inappropriate secretion of antidiuretic hormone after chemotherapy with vinorelbine
Authors
Hiroaki Kuroda
Masafumi Kawamura
Tai Hato
Kazunori Kamiya
Masahiro Kawakubo
Yotaro Izumi
Masazumi Watanabe
Hirohisa Horinouchi
Koichi Kobayashi
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-007-0636-z

Other articles of this Issue 2/2008

Cancer Chemotherapy and Pharmacology 2/2008 Go to the issue

Clinical Trial Report

Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis

Original Article

Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases

Original Article

Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models

Short Communication

Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse

Original Article

Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study

Clinical Trial Report

Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits